Glofitamab + GemOx superior to rituximab + GemOx for lymphoma
Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at the annual hybrid congress ...
Jun 26, 2024
0
0